International Research in Chinese Medicine
International Research in Chinese Medicine. 2024; 4: (4) ; 10.12208/j.ircm.20240064 .
总浏览量: 361
1 海南橘井泉香供应链管理服务有限责任公司 海南海口
2 江西中医药大学 江西南昌
3 海口市人民医院 海南海口
*通讯作者： 姚杉,单位： 海南橘井泉香供应链管理服务有限责任公司 海南海口；
目的 临床试验中的弱势群体可能会面对更多的风险，因此需要对他们给予更多的关注与保护。方法 通过临床试验现有法规，对弱势受试者加以甄别，并分析该群体的特征及潜在风险，提出相应的保护措施。结果 弱势群体的法规有待完善，临床试验各方也需要对弱势受试者的保护做出更多努力。结论 通过对弱势群体参与临床试验的保障，临床试验的整体质量有望得到进一步提高。
Objective Vulnerable groups in clinical trials may face more risks, so they need more attention and protection. Methods Through the existing regulations on clinical trials, vulnerable subjects are identified, and the characteristics and potential risks of this group are analyzed, and corresponding protection measures are proposed. Results The regulations on vulnerable groups need to be improved, and all parties involved in clinical trials also need to make more efforts to protect vulnerable subjects. Conclusion The overall quality of clinical trials is expected to be further improved by ensuring the participation of vulnerable groups in clinical trials.
[1] WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI. Ethical principles for medical research involving human subjects [EB/OL].2024-10-19[2024-01-05]https://jamanetwork.com/journals/jama/fullarticle/ 2825290.
[2] 国家药品监督管理局药品审评中心.关于公开征求ICH《E6（R3）:药物临床试验质量管理规范（GCP）》指导原则及附件1草案的通知[EB/OL].北京:国家药品监督管理局药品审评中心,2023-05-29［2024-01-05］. https://www.cde.org.cn/main/news/viewInfoCommon/2fdefef3f0db1fc1b6b9d3771cd0984a
[3] 国家药品监督管理局,国家卫生健康委员会.药物临床试验质量管理规范 [S].2020.
[4] 国家药品监督管理局,国家卫生健康委员会.医疗器械临床试验质量管理规范[S].2022.
[5] 彭华,王凯戎.受试者保护的法律问题与涉及弱势群体的伦理审查[J].中华医院管理杂志, 2014, 30(12):3.